Literature DB >> 7865175

Dopaminergic function in rat brain after oral administration of calcium-channel blockers or haloperidol. A microdialysis study.

J Reiriz1, S Ambrosio, A Cobos, M Ballarín, E Tolosa, N Mahy.   

Abstract

Microdialysis technique was used to study the effects of both acute and repeated oral administration of calcium-channel blockers (flunarizine, cinnarizine, verapamil, nifedipine and nicardipine) in dopaminergic function in rat brain and to compare them to the effects of haloperidol. Acute flunarizine, nicardipine or haloperidol increased extracellular levels of dopamine (DA) or metabolites. After repeated (18 days) administration, nicardipine, nifedipine, verapamil or haloperidol increased and flunarizine decreased extracellular striatal levels of dopamine or metabolites. Chronic treatment with calcium-channel blockers or haloperidol failed to block K(+)-evoked release of dopamine. This suggests that the calcium-channel blockers used in this study do not influence calcium entry necessary for DA release. An acute challenge with haloperidol caused either no change or a decrease in extracellular levels of DA or metabolites after repeated administration of calcium-channel blockers or haloperidol. This is considered to be due to the lesser response of dopaminergic neurons because of treatment. A neuroleptic-like mechanism of action together with a decrease in firing activity and/or a reduced dopamine re-uptake of dopaminergic neurons are considered.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7865175     DOI: 10.1007/bf01271566

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  46 in total

1.  Inhibition of high affinity synaptosomal uptake systems by verapamil.

Authors:  R McGee; J E Schneider
Journal:  Mol Pharmacol       Date:  1979-11       Impact factor: 4.436

2.  Verapamil concentrations in cerebrospinal fluid after oral administration.

Authors:  A R Doran; P K Narang; C Y Meigs; O M Wolkowitz; A Roy; A Breier; D Pickar
Journal:  N Engl J Med       Date:  1985-05-09       Impact factor: 91.245

3.  Use of calcium antagonism for the characterization of drug-evoked dopamine release from the brain of conscious rats determined by microdialysis.

Authors:  B H Westerink; R M Hofsteede; J Tuntler; J B de Vries
Journal:  J Neurochem       Date:  1989-03       Impact factor: 5.372

4.  Stimulation of D-2 dopamine receptors decreases the evoked in vitro release of [3H]acetylcholine from rat neostriatum: role of K+ and Ca2+.

Authors:  B Drukarch; E Schepens; A N Schoffelmeer; J C Stoof
Journal:  J Neurochem       Date:  1989-06       Impact factor: 5.372

5.  Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis.

Authors:  T Zetterström; T Sharp; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1984-10-30       Impact factor: 4.432

6.  Effects of verapamil, diltiazem and ryosidine on the release of dopamine and acetylcholine in rabbit caudate nucleus slices.

Authors:  K Starke; L Späth; T Wichmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

7.  Inhibition of [3H]dopamine uptake by flunarizine.

Authors:  P Devoto; L Pani; A Kuzmin; G De Montis
Journal:  Eur J Pharmacol       Date:  1991-10-02       Impact factor: 4.432

8.  Different effects of L-, N- and T-type calcium channel blockers on striatal dopamine release measured by microdialysis in freely moving rats.

Authors:  T Kato; Y Otsu; Y Furune; T Yamamoto
Journal:  Neurochem Int       Date:  1992-07       Impact factor: 3.921

9.  Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis.

Authors:  A Imperato; G Di Chiara
Journal:  J Neurosci       Date:  1985-02       Impact factor: 6.167

10.  The Ca++-antagonist nimodipine decreases and the Ca++-agonist Bay K 8644 increases catecholamine synthesis in mouse brain.

Authors:  E Pileblad; A Carlsson
Journal:  Neuropharmacology       Date:  1987-01       Impact factor: 5.250

View more
  4 in total

1.  Influence of phasic and tonic dopamine release on receptor activation.

Authors:  Jakob K Dreyer; Kjartan F Herrik; Rune W Berg; Jørn D Hounsgaard
Journal:  J Neurosci       Date:  2010-10-20       Impact factor: 6.167

2.  Modulation of visceral nociception, inflammation and gastric mucosal injury by cinnarizine.

Authors:  Omar M E Abdel-Salam
Journal:  Drug Target Insights       Date:  2007-02-12

3.  Amelioration of the haloperidol-induced memory impairment and brain oxidative stress by cinnarizine.

Authors:  Omar M E Abdel-Salam; Marwa El-Sayed El-Shamarka; Neveen A Salem; Aliaa E M K El-Mosallamy; Amany A Sleem
Journal:  EXCLI J       Date:  2012-08-27       Impact factor: 4.068

Review 4.  Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

Authors:  Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange
Journal:  Pharm Res       Date:  2018-02-15       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.